Three in one offer
pharmaceutical giant Cipla has introduced a three-in-one aids drug called Triomune. The new drug is a combination of stavudine, lamivudine and nevirapine. Cipla could synthesise the drug because Indian laws allow generic copies to be made. The generic drug would remain one of its kind, as the patent holders of the three drugs are unlikely to form an alliance for a similar offer. Triomune has several advantages over the three drugs. With its introduction, the treatment cost has been slashed from Rs 2,000 to Rs 1,800. Along with this, the dosage has also been reduced
Related Content
- Food waste index report 2024
- Global waste management outlook 2024
- Rehabilitation in health financing: opportunities on the way to universal health coverage
- Regional overview of food security and nutrition in Europe and Central Asia 2023: statistics and trends
- Order of the Supreme Court regarding the of land of DSIIDC at Ranikhera-Mundka which was reserved for waste management, 31/07/2023
- Electric mobility in public transport: a guidebook for Asia-Pacific countries